Patents by Inventor Kallanthottathil G. Rajeev

Kallanthottathil G. Rajeev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ligand-conjugated monomers
    Patent number: 8404862
    Abstract: This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: March 26, 2013
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Venkitasamy Kesavan
  • iRNA Agents Targeting VEGF
    Publication number: 20130018085
    Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 17, 2013
    Inventors: Antonin de Fougerolles, Maria Frank-Kamenetsky, Muthiah Manoharan, Kallanthottathil G. Rajeev, Philipp Hadwiger
  • METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS
    Publication number: 20130017223
    Abstract: A lipid particle can include a plurality of cationic lipids, such as a first cationic lipid and a second cationic lipid. The first cationic lipid can be selected on the basis of a first property and the second cationic can be selected on the basis of a second property. The first and second properties are complementary. The attributes of the lipid particle can reflect the selected properties of the cationic lipids, and the complementary nature of those properties.
    Type: Application
    Filed: December 17, 2010
    Publication date: January 17, 2013
    Applicants: The University of British Columbia, ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Michael J Hope, Thomas D. Madden, Pieter R. Cullis, Martin Maier, Muthusamy Jayaraman, Kallanthottathil G. Rajeev, Akin Akinc, Muthiah Manoharan
  • Modified iRNA agents
    Patent number: 8344125
    Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a carbohydrate; or a steroid, e.g., cholesterol, which is optionally substituted with at least one carbohydrate. is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: January 1, 2013
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev
  • Nuclease resistant double-stranded ribonucleic acid
    Patent number: 8334373
    Abstract: This invention relates to modified double-stranded oligoribonucleic acid (dsRNA) having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: December 18, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, Ingo Roehl, Philipp Hadwiger, Tracy Stage Zimmermann, Muthiah Manoharan, Kallanthottathil G. Rajeev, Akin Akinc
  • iRNA agents targeting VEGF
    Patent number: 8293719
    Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: October 23, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin De Fougerolles, Maria Frank-Kamenetsky, Muthiah Manoharan, Kallanthottathil G. Rajeev, Philipp Hadwiger
  • LIPID FORMULATION
    Publication number: 20120183602
    Abstract: The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
    Type: Application
    Filed: January 25, 2012
    Publication date: July 19, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Jianxin CHEN, Steven Ansell, Akin Akinc, Joseph Robert Dorkin, Xiaojun Qin, William Cantley, Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Narayanannair, Muthusamy Jayaraman
  • 5' PHOSPHATE MIMICS
    Publication number: 20120157511
    Abstract: The present invention provides nucleosides and oligonucleotides comprising a 5? phosphate mimics of formula (IVc) or (Vc). One aspect of the present invention relates to modified nucleosides and oligonucleotides comprising such dinucleotide of formula (Ia). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.
    Type: Application
    Filed: July 7, 2010
    Publication date: June 21, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Marija Prhavc, Ivan Zlatev
  • OLIGONUCLEOTIDE END CAPS
    Publication number: 20120142101
    Abstract: Modified nucleic acids are described herein, including pharmaceutical compositions comprising the modified nucleic acids, and methods of using the modified nucleic acids.
    Type: Application
    Filed: July 7, 2010
    Publication date: June 7, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev
  • CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
    Publication number: 20120136042
    Abstract: The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(RN) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z?)(Z?)O-nucleoside, —P(Z?)(Z?)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z?)(Z?)O-Linker-OP(Z??)(Z??)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z?)(Z?)-formula (I), —P(Z?)(Z?)— or -Linker-R; R is LG, -Linker-LG, or has the structure shown below: LG is independently for each occurrence a carbohydrate, e.g.
    Type: Application
    Filed: December 14, 2011
    Publication date: May 31, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, Narayanannair K. JAYAPRAKASH, Martin MAIER
  • LIPID COMPOSITIONS
    Publication number: 20120128760
    Abstract: Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is (F). Also disclosed are methods of producing the cationic lipid of formula (I).
    Type: Application
    Filed: May 5, 2010
    Publication date: May 24, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Michael E. Jung
  • SYNTHETIC METHODS AND DERIVATIVES OF TRIPHOSPHATE OLIGONUCLEOTIDES
    Publication number: 20120107272
    Abstract: The invention features a oligonucleotide of formula I, or pharmaceutically acceptable salts, or prodrugs thereof: which are capable of inducing an anti-viral or an antibacterial response, in particular, the induction of type I IFN, IL-18 and/or IL-1? by binding to RIG-I. The invention relates to methods of making and using modified oligonucleotide comprising at least one triphosphate or analogs thereof. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.
    Type: Application
    Filed: September 2, 2009
    Publication date: May 3, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Ivan Zlatev
  • LIPID FORMULATION
    Publication number: 20120101148
    Abstract: The invention features an improved lipid formulation comprising a cationic lipid of formula (A), a neutral lipid, a sterol and a PEG or PEG-modified lipid, where R1 and R2 are independently alkyl, alkenyl or alkynyl, each can be optionally substituted, and R3 and R4 are independently lower alkyl or R3 and R4 can be taken together to form an optionally substituted heterocyclic ring. In one embodiment, R1 and R2 are independently selected from oleoyl, pamitoyl, steroyl, linoleyl and R3 and R4 are methyl. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
    Type: Application
    Filed: January 29, 2010
    Publication date: April 26, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Akin Aking, William Querbes, Frances M.P. Wong, Joseph R. Dorkin, Xiaojun Qin, William Cantley, Anna Borodovsky, Soma De, Muthiah Manoharan, Muthusamy Jayaraman, Kallanthottathil G. Rajeev
  • NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS
    Publication number: 20120095075
    Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.
    Type: Application
    Filed: August 16, 2011
    Publication date: April 19, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. Rajeev, David Butler, Narayanannair K. Jayaprakash, Muthusamy Jayaraman, Laxman Eltepu
  • Lipid formulation
    Patent number: 8158601
    Abstract: The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: April 17, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Jianxin Chen, Steven Ansell, Akin Akinc, Joseph Robert Dorkin, Xiaojun Qin, William Cantley, Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Narayanannair, Muthusamy Jayaraman
  • NUCLEIC ACID CHEMICAL MODIFICATIONS
    Publication number: 20120071641
    Abstract: The present invention provides nucleosides of formula (1) and oligonucleotides comprising at least one nucleoside of formula (2): Another aspect of the invention relates to a method of inhibiting the expression of a gene in cell, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.
    Type: Application
    Filed: March 2, 2010
    Publication date: March 22, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Alexander V. Kelin, Sudhakar Rao Takkellapati, Shigeo Matsuda
  • LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS
    Publication number: 20120058144
    Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures XIV or XVII.
    Type: Application
    Filed: November 10, 2009
    Publication date: March 8, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Narayanannair, Marco A. Ciufolini
  • LIPID CONTAINING FORMULATIONS
    Publication number: 20120046478
    Abstract: Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.
    Type: Application
    Filed: August 16, 2011
    Publication date: February 23, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. Rajeev, Akin Akinc, Narayanannair K. Jayaprakash, Muthusamy Jayraman, Martin Maier
  • CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION
    Publication number: 20120035115
    Abstract: The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.
    Type: Application
    Filed: September 23, 2009
    Publication date: February 9, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Takeshi Yamada, David Butler, K. Narayanannair Jayaprakash, Muthusamy Jayraman, Shigeo Matsuda, Rajendra K. Pandey, Chang Geng Peng
  • BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
    Publication number: 20120027803
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Application
    Filed: June 3, 2011
    Publication date: February 2, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah MANOHARAN, Martin Maier, Muthusamy Jayaraman, Shigeo Matsuda, Narayanannair K. Jayaprakash, Kallanthottathil G. Rajeev, Akin Akinc, Thomas A. Baillie